Thursday July 17, 3:10 pm ET BOTHELL, Wash., July 17 /PRNewswire-FirstCall/ -- Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS - News ) today announced that it received a notice from the NASDAQ Listing Qualifications Hearings Panel on July 16, 2008 indicating that the NASDAQ Panel has determined to grant Sonus' request to continue the listing of its securities on The NASDAQ Global Market. The Company's continued listing on NASDAQ is subject to its compliance with certain conditions by August 29, 2008, including the implementation of a reverse stock split, the completion of its planned merger with OncoGenex Technologies Inc., and approval from NASDAQ of the combined entity's application for initial listing on The NASDAQ Capital Market upon completion of the merger. "This extension provides the time to implement the resolutions we...
[read full story]